Search results for "Diagnosi"

showing 10 items of 2319 documents

Evaluation of five automated and one manual method for Toxoplasma and human DNA extraction from artificially spiked amniotic fluid.

2018

International audience; Objectives - Molecular detection of Toxoplasma gondii plays a crucial role in the prenatal and neonatal diagnosis of congenital toxoplasmosis (CT). Sensitivity of this diagnosis is partly related to the efficiency of parasite DNA extraction and amplification. DNA extraction methods with automated platforms have been developed. Therefore, it is essential to evaluate them in combination with adequate PCR amplification assays.Methods - In this multisite study, we investigated the suitability of two recent automated procedures for the isolation of Toxoplasma DNA from amniotic fluid (AF) (Magtration system 12GC, PSS and Freedom EVO VacS, Tecan), compared with three other …

0301 basic medicineMicrobiology (medical)[ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyAmniotic fluid030106 microbiologyToxoplasma gondiiPolymerase Chain ReactionSensitivity and SpecificityToxoplasmosis Congenitallaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawparasitic diseasesDiagnosisTaqManHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030212 general & internal medicineDNA extractionPolymerase chain reactionChromatographyCongenital toxoplasmosisbiologyExtraction (chemistry)Toxoplasma gondiiNucleic Acid Hybridization[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral Medicinerep529DNADNA Protozoanbiology.organism_classificationAmniotic FluidDNA extractionCongenital toxoplasmosisrap5293. Good healthInfectious DiseasesPCRchemistry[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieBiological AssayReagent Kits DiagnosticToxoplasmaDNAClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Whole Exome Sequencing Is the Preferred Strategy to Identify the Genetic Defect in Patients With a Probable or Possible Mitochondrial Cause

2018

Mitochondrial disorders, characterized by clinical symptoms and/or OXPHOS deficiencies, are caused by pathogenic variants in mitochondrial genes. However, pathogenic variants in some of these genes can lead to clinical manifestations which overlap with other neuromuscular diseases, which can be caused by pathogenic variants in non-mitochondrial genes as well. Mitochondrial pathogenic variants can be found in the mitochondrial DNA (mtDNA) or in any of the 1,500 nuclear genes with a mitochondrial function. We have performed a two-step next-generation sequencing approach in a cohort of 117 patients, mostly children, in whom a mitochondrial disease-cause could likely or possibly explain the phe…

0301 basic medicineMitochondrial DNANuclear genelcsh:QH426-470DISORDERSMitochondrial diseaseBiologyMOLECULAR DIAGNOSISMtDNA sequencingDNA sequencingDISEASEDiagnostic yield03 medical and health sciencesmedicineGeneticsDNA DELETIONSGenetics(clinical)whole-exome sequencingTRANSFER-RNA-SYNTHETASELACTIC-ACIDOSISGeneGenetics (clinical)Exome sequencingOriginal ResearchGeneticsmtDNA sequencingGenetic heterogeneityMUTATIONSASSEMBLY FACTORSmedicine.diseasePhenotypeMitochondrial diseaselcsh:Geneticsmitochondrial disease030104 developmental biologyHUMAN COMPLEX-IWhole-exome sequencingdiagnostic yieldNext-generation sequencingMolecular Medicinenext-generation sequencingLEIGH-SYNDROMEFrontiers in Genetics
researchProduct

Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs

2018

Fabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by a galactosidase A (a-gal A) deficiency. Central nervous system involvement and chronic white matter lesions are observed in both FD and multiple sclerosis (MS), which can confound the differential diagnosis. We analyzed the GLA gene, which encodes a-gal A, in 86 patients with clinical and neuroradiological findings consistent with MS to determine whether they had FD. We identified four women initially diagnosed with MS who had GLA mutations associated with FD. Our results indicate that family history besides neurological findings should be evaluated in patients with an uncertain diagnosis of MS. Also the involv…

0301 basic medicineNeurological signsPathologymedicine.medical_specialtyCentral nervous systemmultiple sclerosis03 medical and health sciences0302 clinical medicineα galactosidase aMedicinemisdiagnosisFamily historyfabry diseasebusiness.industryMultiple sclerosismedicine.diseaseFabry diseaseResearch Paper: PathologyHyperintensity3. Good health030104 developmental biologymedicine.anatomical_structureOncologyMisdiagnosiDifferential diagnosisbusiness030217 neurology & neurosurgeryOncotarget
researchProduct

L’olfaction dans les troubles dépressifs : intérêts et perspectives

2017

International audience; Research on sensorial interactions with psychiatric diseases and particularly with the depressive syndrome has mainly focused on visual or auditory processes and much less on olfaction. The depressive illness is one of the most frequent psychiatric diagnoses in the community, with approximately one in five women and one in eight men experiencing a major depressive episode during their lifetime. Although genetic, epigenetic, neuroanatomical, neurochemical, neuroendocrinological and neuroimmunological changes can be detected during depression, the etiology of depression remains partly unclear. The current explanatory models are based on two main factors, i.e. pharmacol…

0301 basic medicineOlfactory systemOlfactory sensitivityBipolar disorderContext (language use)OlfactionÉpisode dépressif caractérisé03 medical and health sciences0302 clinical medicineNeurochemicalLimbic systemArts and Humanities (miscellaneous)DiagnosismedicineMajor depressionDiagnosticMajor depressive episodeDepression (differential diagnoses)Olfaction3. Good healthPsychiatry and Mental health030104 developmental biologyMoodmedicine.anatomical_structure[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Trouble bipolairemedicine.symptomPsychologyNeuroscienceSensibilité olfactive030217 neurology & neurosurgeryL'Encéphale
researchProduct

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

2020

Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function varia…

0301 basic medicineOncologyCancer ResearchCancer cellsmedicine.disease_causeurologic and male genital diseases:Male Urogenital Diseases::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Male Urogenital Diseases::Carcinoma Renal Cell [DISEASES]<i>FH</i> gene0302 clinical medicineMalalties hereditàriesMissense mutationFH geneFH gene hereditary leiomyomatosis leiomyomas missense pathogenic variants renal cell cancerRenal cell cancerMutationKidney diseasesHereditary leiomyomatosis:Otros calificadores::Otros calificadores::/genética [Otros calificadores]:enfermedades urogenitales masculinas::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::enfermedades urogenitales masculinas::carcinoma de células renales [ENFERMEDADES]leiomyomasmissense pathogenic variants renal cell cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRare diseases:Geographic Locations::Europe::Spain [GEOGRAPHICALS]Oncology030220 oncology & carcinogenesisCohortCèl·lules cancerosesMalalties raresRenal Cell CancersGenetic disordersmedicine.medical_specialtyMissense pathogenic variantsBiología Celularlcsh:RC254-282Article03 medical and health sciencesLeiomyomasInternal medicine:Other subheadings::Other subheadings::/genetics [Other subheadings]medicineRonyons - Malalties - Espanya:localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS]business.industry:neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::leiomioma::leiomiomatosis [ENFERMEDADES]Retrospective cohort studymedicine.diseaseGenética030104 developmental biologyFumaraseClinical diagnosisHereditary leiomyomatosis and renal cell cancer syndromeMalalties del ronyó:Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Muscle Tissue::Leiomyoma::Leiomyomatosis [DISEASES]hereditary leiomyomatosisbusiness
researchProduct

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

2021

Simple Summary Breast cancer diagnosis at the initial stage of the disease considerably improves prognosis and survival rates. This retrospective study aimed to develop and validate a plasma microRNA signature as a non-invasive biomarker for early-stage breast cancer diagnosis. We confirmed in a testing cohort of 54 BC patients and 89 healthy volunteers the value of a signature based on miR-30b and miR-99a levels in plasma samples for stage I breast cancer detection. Furthermore, our results were blindly validated in a second cohort of 74 breast cancer and 74 healthy samples. The proposed microRNA signature presented high value as a fast, cost-effective, and non-invasive biomarker for early…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyContext (language use)Article03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerInternal medicinemicroRNAmedicineSurvival rateRC254-282plasmabusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancermedicine.diseasemiRNA signatureCirculating MicroRNA030104 developmental biologyOncology030220 oncology & carcinogenesisCohortbiomarkerBiomarker (medicine)businessearly diagnosisCancers
researchProduct

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores

2021

Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and l…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNeoplasm metastasisAge at diagnosisPrognoseDiagnostic accuracylcsh:RC254-282ArticleMetastasis03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinebrain metastasesOverall survivalBrustkrebsMedicineddc:610HirnmetastaseUnivariate analysisbusiness.industryBrainLuminal aLuminal blcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosis030104 developmental biologyOncology030220 oncology & carcinogenesisBreast; CancerPrognostic groupBreast neoplasmsbusinessDDC 610 / Medicine &amp; healthprognostic scoresCancers
researchProduct

High BCR-ABL/GUS(IS) levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib

2017

Abstract Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an unmet need for baseline molecular parameters associated with inadequate imatinib responses. Experimental Design: We correlated BCR–ABL/GUSIS and BCR–ABL/ABL transcripts at diagnosis with the outcome—defined by the 2013 European LeukemiaNet recommendations—of 272 patients newly diagnosed with CML receiving imatinib 400 mg/daily. Applying receiver-operating characteristic curves, we defined BCR–ABL/GUSIS and BCR–ABL/ABL levels associated with lower probabilities of optimal response, failure-free (FFS), event-free (EFS), transform…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyMyeloidBCR-ABL Diagnosis CMLDrug intolerance03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineDiagnosismedicineBCR-ABLCMLneoplasmsABLbusiness.industryCancerMyeloid leukemiaImatinibOncology cancer researchmedicine.diseaseLeukemia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbusinessTyrosine kinasemedicine.drug
researchProduct

MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples

2020

Abstract Background The rising incidence of renal cell carcinomas (RCC) constitutes a significant challenge owing to risk of overtreatment. Because aberrant microRNA (miR) promoter methylation contributes to cancer development, we investigated whether altered miR-30a-5p expression associates with DNA promoter methylation and evaluated the usefulness as clear cell RCC (ccRCC) diagnostic and prognostic markers. Methods Genome-wide methylome and RNA sequencing data from a set of ccRCC and normal tissue samples from The Cancer Genome Atlas (TCGA) database were integrated to identify candidate CpG loci involved in cancer onset. MiR-30a-5p expression and promoter methylation were quantitatively a…

0301 basic medicineOncologyClear cell renal cell carcinomaCancer Researchmedicine.medical_specialty610Urinelcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemicroRNADiagnosisMedicineDNA methylationReceiver operating characteristicmicroRNAbusiness.industryResearchBiomarkermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisLog-rank testClear cell renal cell carcinoma030104 developmental biologyOncologyCpG site030220 oncology & carcinogenesisDNA methylationbusinessClear cellJournal of Experimental & Clinical Cancer Research : CR
researchProduct

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

2017

IF 6.029; International audience; BackgroundThe prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use.Patients and methodsAccording to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study. Primary objective was to compare percentage of patients alive and without recurrence at 2 years in patients with high versus low LI (#NCT02364024). Associations…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentMedizinLeucovorinProspective cohort study[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXOrganoplatinum Compounds/therapeutic useAntineoplastic Combined Chemotherapy ProtocolstudyLymphocytesProspective StudiesProspective cohort studyLeucovorin/therapeutic useMiddle AgedPrognosis3. Good healthColorectal carcinomaOncologyFluorouracil030220 oncology & carcinogenesisPredictive value of testsColonic NeoplasmsBiomarker (medicine)Lymphocytes/pathologyFemaleFluorouracilAdjuvantmedicine.drugAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerFluorouracil/therapeutic useBiomarkers Tumor/analysis03 medical and health sciencesLymphocytes Tumor-InfiltratingPredictive Value of TestsBiomarker; Colorectal carcinoma; Immune response; Prospective cohort study; Oncology; Cancer ResearchInternal medicinemedicineBiomarkers TumorHumansImmune responseSurvival analysisAgedbusiness.industryBiomarkermedicine.diseaseSurvival AnalysisSurgery030104 developmental biologyProspective cohort&nbspMultivariate AnalysisColonic Neoplasms/diagnosisAntineoplastic Combined Chemotherapy Protocols/therapeutic usebusiness
researchProduct